Inovio reports fourth quarter and full year 2023 financial results and operational highlights

Announced substantial progress with lead program, ino-3107, as potential treatment for recurrent respiratory papillomatosis (rrp) positive data announced from phase 1/2 trial orphan drug designation granted by european union  breakthrough therapy designation granted by u.s. food and drug administration (fda) received fda feedback that data from completed phase 1/2 trial can be used to submit biological license application (bla) under accelerated approval program announced plan to submit bla to fda under accelerated approval program in second half of 2024 announced clinical collaboration and supply agreement with coherus biosciences to advance development of ino-3112 in combination with loqtorzi™ (toripalimab-tpzi) combination therapy to be evaluated in a planned phase 3 trial in patients with locoregionally advanced, high-risk, hpv-16/18-positive throat cancer clinical trial design submitted to fda in first quarter 2024; feedback expected in second quarter reported positive phase 1b results for ino-4201 as a potential ebola booster vaccine for rvsv-zebov (ervebo®) prioritized pipeline and reduced 2023 operating expenses by 48% from 2022 ended 2023 with $145.3 million in cash, cash equivalents, and short-term investments projects cash runway into second quarter 2025 management will host conference call today at 4:30 p.m. et plymouth meeting, pa.
INO Ratings Summary
INO Quant Ranking